References
- World Heathy Origination. COVID-19 vaccine tracker and landscape. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines, 2021.
- Science. Novavax’s long-awaited COVID-19 vaccine authorizations offer an alternative to mRNA. Available from: https://www.science.org/content/article/novavax-s-long-awaited-covid-19-vaccine-authorizations-offer-alternative-mrna, 2021.
- World Heathy Origination. WHO coronavirus (COVID-19) dashboard. Available from: https://covid19.who.int, 2021.
- Clover Biopharmaceuticals. Clover’s COVID-19 vaccine candidate demonstrates 79% efficacy against delta in global phase 2/3 SPECTRA trial dominated by variants of concern and interest. Available from: https://www.cloverbiopharma.com/news/83.html, 2021.
- He Q, Mao Q, Zhang J, et al. COVID-19 vaccines: current understanding on immunogenicity, safety, and further considerations. Front Immunol. 2021;12:669339.
- Zhang J, He Q, An C, et al. Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine. Emerg Microbes Infect. 2021 Dec;10(1):1598–1608.
- Nie J, Li Q, Wu J, et al. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerg Microbes Infec. 2020 Dec;9(1):680–686.
- Arunachalam PS, Scott MKD, Hagan T, et al. Systems vaccinology of the BNT162b2 mRNA vaccine in humans. Nature. 2021 Aug;596(7872):410–416.
- Burgdorf S, Kautz A, Bohnert V, et al. Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8T cell activation. Science. 2007 Apr 27;316(5824):612–616.
- Xu S, Yang K, Li R, et al. mRNA Vaccine Era-Mechanisms, Drug Platform and Clinical Prospection. Int J Mol Sci. 2020 Sep 9;21(18):6582.
- Sokolovska A, Hem SL, HogenEsch H. Activation of dendritic cells and induction of CD4+ T cell differentiation by aluminum-containing adjuvants. Vaccine. 2007 Jun 6;25(23):4575–4585.
- Pizzuto M, Gangloff M, Scherman D, et al. Toll-like receptor 2 promiscuity is responsible for the immunostimulatory activity of nucleic acid nanocarriers. J Control Release. 2017 Feb 10;247:182–193.
- Zhang H, You X, Wang X, et al. Delivery of mRNA vaccine with a lipid-like material potentiates antitumor efficacy through Toll-like receptor 4 signaling. Proc Natl Acad Sci U S A. 2021 Feb 9;118(6):e2005191118.
- Linares-Fernandez S, Lacroix C, Exposito JY, et al. Tailoring mRNA vaccine to balance innate/adaptive immune response. Trends Mol Med. 2020 Mar;26(3):311–323.
- Jensen S, Thomsen AR. Sensing of RNA viruses: a review of innate immune receptors involved in recognizing RNA virus invasion. J Virol. 2012 Mar;86(6):2900–2910.
- Burke JM, Moon SL, Matheny T, et al. RNase l reprograms translation by widespread mRNA turnover escaped by antiviral mRNAs. Mol Cell. 2019 Sep;75(6):1203–1217.e5.
- Kowalczyk A, Doener F, Zanzinger K, et al. Self-adjuvanted mRNA vaccines induce local innate immune responses that lead to a potent and boostable adaptive immunity. Vaccine. 2016 Jul 19;34(33):3882–3893.
- Bergamaschi C, Terpos E, Rosati M, et al. Systemic IL-15, IFN-γ, and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients. Cell Rep. 2021 Aug 10;36(6):109504.
- Ivanova EN, Devlin JC, Buus TB, et al. SARS-CoV-2 mRNA vaccine elicits a potent adaptive immune response in the absence of IFN-mediated inflammation observed in COVID-19. Preprint. medRxiv. 2021;2021.04.20.21255677.
- Feng S, Phillips DJ, White T, et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med. 2021 Nov;27(11):2032–2040.
- Gilbert PB, Montefiori DC, McDermott AB, et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. 2021. Available from: https://www.science.org/doi/epdf/10 .1126/science.abm3425.
- Yang S, Li Y, Dai L, et al. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect Dis. 2021;21(8):1107–1119.
- Miller MA, Ganesan AP, Luckashenak N, et al. Endogenous antigen processing drives the primary CD4+ T cell response to influenza. Nat Med. 2015 Oct;21(10):1216–1222.
- Osorio F, Lambrecht BN, Janssens S. Antigen presentation unfolded: identifying convergence points between the UPR and antigen presentation pathways. Curr Opin Immunol. 2018 Jun;52:100–107.
- Ranjan K, Hedl M, Sinha S, et al. Ubiquitination of ATF6 by disease-associated RNF186 promotes the innate receptor-induced unfolded protein response. J Clin Invest. 2021 Sep 1;131(17).
- Iavarone C, O'Hagan DT, Yu D, et al. Mechanism of action of mRNA-based vaccines. Expert Rev Vaccines. 2017 Sep;16(9):871–881.